Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Summary

This is an Early Feasibility Study (EFS) investigating the use of the Hemopurifier to clear immunosuppressive exosomes in combination with pembrolizumab (Keytruda) in the front line setting, in patients with advanced and/or metastatic squamous cell carcinoma of the head and neck.

Timeline

Start

2020-10-22

Primary completion

2022-11-14

Completion

2022-11-14

Drugs

Indications